Let's get ready for ESMO 2025!

Multiplicity in oncology randomized trials: an approach to the KEYNOTE-B96 trial with a detour via bevacizumab

PD(L1) blockade in patients with ovarian cancer…

Oct 9 •

Timothée Olivier

Adjuvant CDK4/6 Inhibitors Still Under Debate: Preparing for the NATALEE and monarchE Updates at ESMO 2025.

With nearly 40% of patients newly diagnosed with breast cancer potentially eligible, the stakes are high.

Oct 5 •

Timothée Olivier

The POTOMAC Trial

In february 2019, the POTOMAC trial was announced, focusing on high-risk non-muscle invasive bladder cancer (NMIBC).

Oct 4 •

Dries Develtere

Will PSMAddition Deliver?

I’m thrilled to share a guest post by Dries Develtere as part of our “Let’s Get Ready for ESMO 2025!” series.

Sep 28 •

Dries Develtere

Let's get ready for ESMO 2025 with the KEYNOTE-905 trial! Does EV-Pembro in perioperative bladder cancer set a new standard of care?

We should wait to see the data at ESMO before making any decisions.

Sep 25 •

Timothée Olivier

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts